Menu

Connect

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

+1 617.871.2098  phone
+1 617.871.2099  fax

For all general inquiries, please contact:

For employment verification, please visit Truework.

Follow Us

Investor Inquiries

Kristen K. Sheppard, Esq
VP, Investor Relations

 

Media Inquiries

Mercedes Carrasco
Director, Corporate Communications
media@akebia.com

 

Partnering Inquiries

Patrick Walsh
VP, Business Development
partnering@akebia.com

 

Sponsorship & Donation Inquiries

Susan Brady
Manager, Advocacy & Corporate Communications
sponsorships@akebia.com

 

Located in the heart of Kendall Square

DIRECTIONS

News

October 26, 2020

Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights

October 23, 2020

Akebia Presents Results from its PRO₂TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 Reimagined

October 22, 2020

Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
VIEW ALL NEWS

DSE-US-0070

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098  phone
+1 617.871.2099  fax

Contact Us